1. Home
  2. GNLX vs ACOG Comparison

GNLX vs ACOG Comparison

Compare GNLX & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genelux Corporation

GNLX

Genelux Corporation

HOLD

Current Price

$4.32

Market Cap

202.4M

Sector

Health Care

ML Signal

HOLD

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$5.52

Market Cap

115.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNLX
ACOG
Founded
2001
2000
Country
United States
Canada
Employees
N/A
57
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
202.4M
115.5M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
GNLX
ACOG
Price
$4.32
$5.52
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
1
Target Price
$19.75
$18.00
AVG Volume (30 Days)
187.8K
84.0K
Earning Date
11-05-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$7,427,199.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$143.70
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.99
$3.75
52 Week High
$8.54
$11.54

Technical Indicators

Market Signals
Indicator
GNLX
ACOG
Relative Strength Index (RSI) 35.71 35.86
Support Level $4.37 $5.66
Resistance Level $4.75 $6.74
Average True Range (ATR) 0.42 0.41
MACD -0.04 -0.01
Stochastic Oscillator 8.99 0.00

Price Performance

Historical Comparison
GNLX
ACOG

About GNLX Genelux Corporation

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: